PAVmed (PAVM) to Release Earnings on Thursday

PAVmed (NASDAQ:PAVM) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, November 14th. Analysts expect PAVmed to post earnings of ($1.30) per share for the quarter.

PAVmed (NASDAQ:PAVM) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.84) earnings per share (EPS) for the quarter. The business had revenue of $0.98 million during the quarter. On average, analysts expect PAVmed to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

PAVmed Trading Up 0.9 %

PAVM opened at $1.12 on Tuesday. The stock has a fifty day simple moving average of $1.23 and a two-hundred day simple moving average of $1.20. The company has a market cap of $11.66 million, a price-to-earnings ratio of -0.14 and a beta of 0.69. PAVmed has a 12-month low of $0.60 and a 12-month high of $4.88.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their price objective on PAVmed from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, September 10th.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.